news
Serina advances Parkinson's drug trial after safety review
Serina Therapeutics got the green light to move its Parkinson's drug, SER-252, into the second cohort of its Phase 1b trial after a safety committee review. The drug, which is designed to sustain apomorphine exposure, showed a consistent pharmacokinetic profile in patients. This means they can test higher doses and watch for effectiveness against Parkinson's symptoms.
Serina Therapeutics got the green light to move its Parkinson's drug, SER-252, into the second cohort of its Phase 1b trial after a safety committee review. The drug, which is designed to sustain apomorphine exposure, showed a consistent pharmacokinetic profile in patients. This means they can test higher doses and watch for effectiveness against Parkinson's symptoms.
The architecture take
It's always a good sign when an independent safety committee waves a new drug into the next trial phase. SER-252 is a modified apomorphine, a dopamine agonist that's been around for ages to manage Parkinson's motor fluctuations. The catch with traditional apomorphine is its short half-life, meaning frequent dosing. This new version aims to fix that, offering sustained exposure, which could mean less dosing and more stable dopamine levels. Think about what stable dopamine means for someone whose nervous system struggles to produce it consistently. This isn't just about movement; it's about sleep, mood, and cognitive load. If it works, it might smooth out the wild swings people with Parkinson's experience, which is a huge win for their overall state. I'm watching for the next update on efficacy, not just safety. Stable states are everything.